Revisiting Secondary Information Related to Pharmacogenetic Testing

9Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.

Cite

CITATION STYLE

APA

Haga, S. B. (2021). Revisiting Secondary Information Related to Pharmacogenetic Testing. Frontiers in Genetics, 12. https://doi.org/10.3389/fgene.2021.741395

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free